The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
<p><strong>Background</strong> Molecular diagnostics are considered the most promising route to achievement of rapid, universal drug susceptibility testing for Mycobacterium tuberculosis complex (MTBC). We aimed to generate a WHO-endorsed catalogue of mutations to serve as a global...
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Язык: | English |
| Опубликовано: |
Elsevier
2022
|
| _version_ | 1826307466027073536 |
|---|---|
| author | Walker, T Miotto, P Köser, CU Fowler, PW Knaggs, J Iqbal, Z Hunt, M Chindelevitch, L Farhat, M Cirillo, D Comas, I Posey, J Omar, SV Peto, T Suresh, A Uplekar, S Laurent, S Brankin, A Carter, J Clifton, D Earle, S Hoosdally, S Lachapelle, A Rodger, G Roohi, A Thuong, N Thwaites, G Wilson, D Crook, D Ismail, N Rodwell, T |
| author_facet | Walker, T Miotto, P Köser, CU Fowler, PW Knaggs, J Iqbal, Z Hunt, M Chindelevitch, L Farhat, M Cirillo, D Comas, I Posey, J Omar, SV Peto, T Suresh, A Uplekar, S Laurent, S Brankin, A Carter, J Clifton, D Earle, S Hoosdally, S Lachapelle, A Rodger, G Roohi, A Thuong, N Thwaites, G Wilson, D Crook, D Ismail, N Rodwell, T |
| author_sort | Walker, T |
| collection | OXFORD |
| description | <p><strong>Background</strong>
Molecular diagnostics are considered the most promising route to achievement of rapid, universal drug susceptibility testing for Mycobacterium tuberculosis complex (MTBC). We aimed to generate a WHO-endorsed catalogue of mutations to serve as a global standard for interpreting molecular information for drug resistance prediction.</p>
<p><strong>Methods</strong>
In this systematic analysis, we used a candidate gene approach to identify mutations associated with resistance or consistent with susceptibility for 13 WHO-endorsed antituberculosis drugs. We collected existing worldwide MTBC whole-genome sequencing data and phenotypic data from academic groups and consortia, reference laboratories, public health organisations, and published literature. We categorised phenotypes as follows: methods and critical concentrations currently endorsed by WHO (category 1); critical concentrations previously endorsed by WHO for those methods (category 2); methods or critical concentrations not currently endorsed by WHO (category 3). For each mutation, we used a contingency table of binary phenotypes and presence or absence of the mutation to compute positive predictive value, and we used Fisher's exact tests to generate odds ratios and Benjamini-Hochberg corrected p values. Mutations were graded as associated with resistance if present in at least five isolates, if the odds ratio was more than 1 with a statistically significant corrected p value, and if the lower bound of the 95% CI on the positive predictive value for phenotypic resistance was greater than 25%. A series of expert rules were applied for final confidence grading of each mutation.</p>
<p><strong>Findings</strong>
We analysed 41 137 MTBC isolates with phenotypic and whole-genome sequencing data from 45 countries. 38 215 MTBC isolates passed quality control steps and were included in the final analysis. 15 667 associations were computed for 13 211 unique mutations linked to one or more drugs. 1149 (7·3%) of 15 667 mutations were classified as associated with phenotypic resistance and 107 (0·7%) were deemed consistent with susceptibility. For rifampicin, isoniazid, ethambutol, fluoroquinolones, and streptomycin, the mutations' pooled sensitivity was more than 80%. Specificity was over 95% for all drugs except ethionamide (91·4%), moxifloxacin (91·6%) and ethambutol (93·3%). Only two resistance mutations were identified for bedaquiline, delamanid, clofazimine, and linezolid as prevalence of phenotypic resistance was low for these drugs.</p>
<p><strong>Interpretation</strong>
We present the first WHO-endorsed catalogue of molecular targets for MTBC drug susceptibility testing, which is intended to provide a global standard for resistance interpretation. The existence of this catalogue should encourage the implementation of molecular diagnostics by national tuberculosis programmes.</p> |
| first_indexed | 2024-03-07T07:03:32Z |
| format | Journal article |
| id | oxford-uuid:a022c3e2-c945-4c28-9e63-2a657ed1fb12 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:03:32Z |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:a022c3e2-c945-4c28-9e63-2a657ed1fb122022-04-04T09:49:29ZThe 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a022c3e2-c945-4c28-9e63-2a657ed1fb12EnglishSymplectic ElementsElsevier2022Walker, TMiotto, PKöser, CUFowler, PWKnaggs, JIqbal, ZHunt, MChindelevitch, LFarhat, MCirillo, DComas, IPosey, JOmar, SVPeto, TSuresh, AUplekar, SLaurent, SBrankin, ACarter, JClifton, DEarle, SHoosdally, SLachapelle, ARodger, GRoohi, AThuong, NThwaites, GWilson, DCrook, DIsmail, NRodwell, T<p><strong>Background</strong> Molecular diagnostics are considered the most promising route to achievement of rapid, universal drug susceptibility testing for Mycobacterium tuberculosis complex (MTBC). We aimed to generate a WHO-endorsed catalogue of mutations to serve as a global standard for interpreting molecular information for drug resistance prediction.</p> <p><strong>Methods</strong> In this systematic analysis, we used a candidate gene approach to identify mutations associated with resistance or consistent with susceptibility for 13 WHO-endorsed antituberculosis drugs. We collected existing worldwide MTBC whole-genome sequencing data and phenotypic data from academic groups and consortia, reference laboratories, public health organisations, and published literature. We categorised phenotypes as follows: methods and critical concentrations currently endorsed by WHO (category 1); critical concentrations previously endorsed by WHO for those methods (category 2); methods or critical concentrations not currently endorsed by WHO (category 3). For each mutation, we used a contingency table of binary phenotypes and presence or absence of the mutation to compute positive predictive value, and we used Fisher's exact tests to generate odds ratios and Benjamini-Hochberg corrected p values. Mutations were graded as associated with resistance if present in at least five isolates, if the odds ratio was more than 1 with a statistically significant corrected p value, and if the lower bound of the 95% CI on the positive predictive value for phenotypic resistance was greater than 25%. A series of expert rules were applied for final confidence grading of each mutation.</p> <p><strong>Findings</strong> We analysed 41 137 MTBC isolates with phenotypic and whole-genome sequencing data from 45 countries. 38 215 MTBC isolates passed quality control steps and were included in the final analysis. 15 667 associations were computed for 13 211 unique mutations linked to one or more drugs. 1149 (7·3%) of 15 667 mutations were classified as associated with phenotypic resistance and 107 (0·7%) were deemed consistent with susceptibility. For rifampicin, isoniazid, ethambutol, fluoroquinolones, and streptomycin, the mutations' pooled sensitivity was more than 80%. Specificity was over 95% for all drugs except ethionamide (91·4%), moxifloxacin (91·6%) and ethambutol (93·3%). Only two resistance mutations were identified for bedaquiline, delamanid, clofazimine, and linezolid as prevalence of phenotypic resistance was low for these drugs.</p> <p><strong>Interpretation</strong> We present the first WHO-endorsed catalogue of molecular targets for MTBC drug susceptibility testing, which is intended to provide a global standard for resistance interpretation. The existence of this catalogue should encourage the implementation of molecular diagnostics by national tuberculosis programmes.</p> |
| spellingShingle | Walker, T Miotto, P Köser, CU Fowler, PW Knaggs, J Iqbal, Z Hunt, M Chindelevitch, L Farhat, M Cirillo, D Comas, I Posey, J Omar, SV Peto, T Suresh, A Uplekar, S Laurent, S Brankin, A Carter, J Clifton, D Earle, S Hoosdally, S Lachapelle, A Rodger, G Roohi, A Thuong, N Thwaites, G Wilson, D Crook, D Ismail, N Rodwell, T The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis |
| title | The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis |
| title_full | The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis |
| title_fullStr | The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis |
| title_full_unstemmed | The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis |
| title_short | The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis |
| title_sort | 2021 who catalogue of mycobacterium tuberculosis complex mutations associated with drug resistance a genotypic analysis |
| work_keys_str_mv | AT walkert the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT miottop the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT kosercu the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT fowlerpw the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT knaggsj the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT iqbalz the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT huntm the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT chindelevitchl the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT farhatm the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT cirillod the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT comasi the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT poseyj the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT omarsv the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT petot the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT suresha the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT uplekars the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT laurents the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT brankina the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT carterj the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT cliftond the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT earles the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT hoosdallys the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT lachapellea the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT rodgerg the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT roohia the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT thuongn the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT thwaitesg the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT wilsond the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT crookd the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT ismailn the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT rodwellt the2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT walkert 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT miottop 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT kosercu 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT fowlerpw 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT knaggsj 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT iqbalz 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT huntm 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT chindelevitchl 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT farhatm 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT cirillod 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT comasi 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT poseyj 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT omarsv 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT petot 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT suresha 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT uplekars 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT laurents 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT brankina 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT carterj 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT cliftond 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT earles 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT hoosdallys 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT lachapellea 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT rodgerg 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT roohia 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT thuongn 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT thwaitesg 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT wilsond 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT crookd 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT ismailn 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis AT rodwellt 2021whocatalogueofmycobacteriumtuberculosiscomplexmutationsassociatedwithdrugresistanceagenotypicanalysis |